SNC'21 | LIVE
SiNAPSA Neuroscience Conference 2021
Thursday, 23 September 2021
Opening of the SNC'21 | 13:45–14:00
13:45–13:50 Maja Bresjanac
13:50–13:55 Blaž Koritnik
13:55–14:00 Viktorija Radotič
Symposium | 14:00–16:00
SARS-COV-2 AND BRAIN
Chair: Maja Bresjanac
14:00–14:30 Neuro-COVID - What it is and what it is not / Raimund Helbok
14:30–15:00 Neurological Associations of COVID-19 Vaccines / Jennifer Frontera
15:00–15:30 Learning during the pandemic: mapping potential educational inequalities across Europe / Zsuzsa Blaskó
15:30–16:00 Cognitive and Neurological Consequences of COVID-19 / Adrian Owen
Symposium | 16:00–18:00
METABOLIC BRAIN IMAGING IN NEURODEGENERATIVE DISORDERS / Chair: Matej Perovnik and Maja Trošt
16:00–16:30 Mechanisms of tau pathology spreading in Alzheimer’s disease and 4R tauopathies / Nicolai Franzmeier
16:30–16:45 Developing and Interpreting a Deep Learning Model for Alzheimer’s Disease Tracking / Alison Deatsch
16:45–17:00 Technical Factors Affecting Image Quality in PET / Mauro Namías
17:00–17:15 Cognition-related functional topographies in Parkinson’s disease: Localized loss of the ventral default mode network / Katharina A Schindlbeck
17:15–17:30 Metabolic correlates in PSP clinical subtypes / Gloria Martí-Andrés
17:30–17:45 Specific Metabolic Brain Patterns in Alzheimer’s dementia and dementia with Lewy bodies / Matej Perovnik
17:45–18:00 Correlations between brain metabolism and neuropathology in sporadic Creutzfeldt-Jakob disease / Tomaž Rus
Plenary talk | 18:15–19:00
CAN BRAIN IMAGING UNRAVEL THE TANGLED WEB OF NEURODEGENERATION? / Thilo van Eimeren
Friday, 24 September 2021
Short Oral Presentations Session I | 11:00–12:00
Dr. Janez Faganel Memorial lecture | 12:00–12:45
SMALL FIBER NEUROPATHY / Giuseppe Lauria
Symposium | 13:00–14:30
DEEP BRAIN STIMULATION FOR MOVEMENT DISORDERS - A NEUROIMAGING PERSPECTIVE
Chair: Maja Trošt and Dejan Georgiev
13:00–13.15 Non-motor symptoms in Parkinson's disease and Dystonia: Neuroimaging perspective / Vladimira Vuletić
13:15–13:30 The effect of Deep Brain Stimulation on Brain Metabolism in Movement Disorders / Maja Trošt
13:30–13:40 Parkinson's disease as a network disorder: Lessons from connectivity studies / Rok Berlot
13:40–13:50 Frequency modulation in deep brain stimulation: Does it work and is there neuroimaging proof of its action?
/ Dejan Georgiev
13:50–14:00 Impulsivity in STN-DBS PD: More than a unitary phenomenon / Tjaša Mlinarič
14:00–14:10 Effects of subthalamic nucleus deep brain stimulation on language in advanced Parkinson's disease / Živa Drakulić
Workshop | 15:00–18:45
EDUCATIONAL WORKSHOP ON CNS PROTEIN MISFOLDING
Chair: Lana Blinc
15:00–15:45 | Proteostasis Collapse: A Basis for Aging and Neurodegenerative Diseases / Richard I. Morimoto
15:45–16:15 | An update on Tau-related diseases / Gabor G. Kovacs
16:15–16:45 | TDP-43 proteinopathies / Boris Rogelj
16:45–17:15 | Now it is time for research to crack Parkinson’s disease / Patrik Brundin
17:15–17:45 | Huntington's disease / Roger A. Barker
17:45–18:15 | Transmissible Spongiform Encephalopathies / Adriano Aguzzi
18:15–18:45 | A structural biologist's view of neuroscience / Holger Wille
AOŽ Memorial lecture | 19:00–19:45
GENETIC PRION DISORDERS AND PATIENT-SCIENTIST'S MANDATE / Sonia M. Vallabh
Neuroscience and Society Dialogue | 19:45–20:30
Saturday, 25 September 2021
Short Oral Presentations Session II | 11:00–12:00
Plenary talk | 12:00–12:45
SYSTEMS ALL THE WAY DOWN: STUDYING MENTAL HEALTH PROBLEMS AS BIOPSYCHOSOCIAL SYSTEMS / Eiko Fried
Symposium | 13:00–15:00
MUSIC AND BRAIN: EVIDENCE-BASED MUSIC INTERVENTIONS IN MEDICINE
Chair: Igor M. Ravnik and Uroš Kovačič
13:00–13:30 Neurology of Music and Brain / Daniele Schoen
13:30–14:00 Research towards evidence-based music interventions / Stefan Koelsch
14:00–14:30 The mother's voice, singing and speaking, as a special tool for early interventions in the NICU / Manuela Filippa
14:30–15:00 Heart rate variability in relation to self-selected music or music genres preselected by the researchers / Uroš Kovačič
Symposium | 15:00–17:00
BRAIN HEALTH ACCROSS THE LIFESPAN – FINDINGS FROM THE LIFEBRAIN PROJECT
Chair: Isabelle Budin-Ljøsne
15:00–15:30 Ageing and brain imaging in Lifebrain / Klaus P. Ebmeier for Lifebrain Consortium
15:30–16:00 What can blood biomarkers tell us about the brain? / Christian A. Drevon
16:00–16:30 What is brain health? Perceptions of respondents to the Global Brain Health Survey
/ Isabelle Budin-Ljøsne for Lifebrain Consortium
16:30–17:00 Brain asymmetry in aging and Alzheimer's disease / James M. Roe
Plenary talk | 17:00–17:45
EXTRACELLULAR VESICLES AS STRESS SIGNALS: IDENTIFYING NOVEL MECHANISMS OF NEURODEVELOPMENTAL PROGRAMMING / Tracy Bale
SNC'21 Closing | 17:45–18:00
17:45–18:00 Maja Bresjanac
Short Oral Presentations (Posters)
Videtič Paska A: DNA methylation of BDNF and COMT candidate genes in Alzheimer's disease
Ulbl J: The Alzheimer’s Disease Assessment Scale–Cognitive Subscale (ADAS-Cog): standardisation ...
Roumpea G: Effect of repetitive transcranial magnetic stimulation on language performance ...
Jan V: Expression on Na+,K+-ATPase isoenzymes and myokines in cultured human myotubes innervated ...
Ghosh D: HMGB1 inhibition attenuates lipopolysaccharide LPS induced neuroinflammation ...
Perovnik M: Educated vs. lay public view of neuroscience and science based brain health ...
Pain P: Role of PDGFRα-Integrin interactions in Anoikis resistance mediated glioblastoma progression
Kuder A: Facilitation of the use of music in Slovene health care
In this section please find answers to the questions exceeding the available discussion time.
SARS-CoV-2 and Brain Symposium
For Prof. Raimund Helbok (Neuro-COVID: what it is and what it is not)
Q: Do any broadly accepted treatment options exist for persistent post-COVID olfactory dysfunction that does not resolve on its own?
A: No randomised controlled trial data available. Based on previous experience (viral diseases with hyposmia) smelling training can be tried, some observational studies show benefit. I would not recommend corticoid treatment althoug some countries/ENR doctors do so...
Q: Could be depression and anxiety associated with obligatory social isolation during acute phase of disease?
A: Sure, especially in patients with preexisting preclinical/clinical disorders.
Q: Are there gender differences in neurological consequences of Covid-19?
A: Interesting question: in general, women do better, however, it seems that this is more true in hospitalized patients. We have seen that being a women is strongly associated with long term effects in non-hospitalized patients.
Q: Have you spotted any differences in long term effects between those who were vaccinated before having been infected with Covid - and those who weren't?
A: There are currently insufficient data to seriously answer this question, sorry. We are studying the variants now.
Q: How can Slovenian neurologists join the EANcore?
A: Please, contact either me or the EAN using this Email: firstname.lastname@example.org
For Prof. Jennifer Frontera (Neurological Associations of COVID-19 Vaccines)
Q: Would you recommend classical protein vaccines more than novel ones (mRNA, DNA, ...)?
A: At this point the data on efficacy and safety of mRNA vaccines is very robust. The nanoparticle vaccine Novavax also has promising data but there is much less real world experience with it at this point. The mRNA vaccines appear to perform better than the adenovirus vaccines, though any vaccination is better than no vaccination.
Q: What pathologies are included in the »movement disorder« in your data?
A: Movement disorder included primarily tremor, but also blepharospasm and dystonia were reported.